The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 12, 2019

Filed:

Jul. 24, 2017
Applicants:

Genentech, Inc., South San Francisco, CA (US);

Constellation Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Marc Adler, South San Francisco, CA (US);

Daniel J. Burdick, South San Francisco, CA (US);

Terry Crawford, South San Francisco, CA (US);

Martin Duplessis, Cambridge, MA (US);

Steven R. Magnuson, South San Francisco, CA (US);

Christopher G. Nasveschuk, Cambridge, MA (US);

F. Anthony Romero, South San Francisco, CA (US);

Yong Tang, Cambridge, MA (US);

Vickie Hsiao-Wei Tsui, South San Francisco, CA (US);

Shumei Wang, South San Francisco, CA (US);

Assignees:

GENENTECH, INC., South San Francisco, CA (US);

CONSTELLATION PHARMACEUTICALS, INC., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention relates to compounds of formula (I): and to salts thereof, wherein R-Rhave any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.


Find Patent Forward Citations

Loading…